{"id":"valpromide","rwe":[{"pmid":"40856063","year":"2025","title":"Valproic Acid Inhibits RhoA-Mediated Vascular Smooth Muscle Cell Contraction.","finding":"","journal":"Journal of Korean medical science","studyType":"Clinical Study"},{"pmid":"40700674","year":"2025","title":"Trends in Prenatal Exposure to Antiseizure Medications Over the Past Decade: A Nationwide Study.","finding":"","journal":"Neurology","studyType":"Clinical Study"},{"pmid":"39426425","year":"2024","title":"LC-MS/MS profiling of the poisonous wild mushroom, Entoloma mastoideum, (Entolomataceae, Basidiomycota) in Sabah (Northern Borneo), Malaysia.","finding":"","journal":"Toxicon : official journal of the International Society on Toxinology","studyType":"Clinical Study"},{"pmid":"38635661","year":"2024","title":"Transcriptome analysis of Burkitt lymphoma cells treated with anti-convulsant drugs that are inhibitors of Epstein-Barr virus lytic reactivation.","finding":"","journal":"PloS one","studyType":"Clinical Study"},{"pmid":"37838533","year":"2023","title":"Corrigendum to \"Valproate, divalproex, valpromide: Are the differences in indications justified?\" [Biomed. Pharmacother., 158 (2023) 114051].","finding":"","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","studyType":"Clinical Study"}],"tags":[{"label":"valpromide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"N03AG02","category":"atc"},{"label":"Active","category":"status"},{"label":"Anticonvulsants","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{"safetySignals":[{"llr":169.67,"date":"","count":45,"signal":"Poisoning deliberate","source":"DrugCentral FAERS","actionTaken":"Reported 45 times (LLR=170)"},{"llr":125.893,"date":"","count":56,"signal":"Coma","source":"DrugCentral FAERS","actionTaken":"Reported 56 times (LLR=126)"},{"llr":85.371,"date":"","count":28,"signal":"Hypothermia","source":"DrugCentral FAERS","actionTaken":"Reported 28 times (LLR=85)"},{"llr":70.946,"date":"","count":65,"signal":"Toxicity to various agents","source":"DrugCentral FAERS","actionTaken":"Reported 65 times (LLR=71)"},{"llr":69.884,"date":"","count":36,"signal":"Suicide attempt","source":"DrugCentral FAERS","actionTaken":"Reported 36 times (LLR=70)"},{"llr":63.958,"date":"","count":16,"signal":"Meningioma","source":"DrugCentral FAERS","actionTaken":"Reported 16 times (LLR=64)"},{"llr":60.086,"date":"","count":26,"signal":"Hepatocellular injury","source":"DrugCentral FAERS","actionTaken":"Reported 26 times (LLR=60)"},{"llr":58.936,"date":"","count":10,"signal":"Alkalosis hypochloraemic","source":"DrugCentral FAERS","actionTaken":"Reported 10 times (LLR=59)"},{"llr":56.55,"date":"","count":36,"signal":"Bradycardia","source":"DrugCentral FAERS","actionTaken":"Reported 36 times (LLR=57)"},{"llr":52.922,"date":"","count":8,"signal":"Hypometabolism","source":"DrugCentral FAERS","actionTaken":"Reported 8 times (LLR=53)"}],"commonSideEffects":[{"effect":"Poisoning deliberate","drugRate":"LLR 170","severity":"common"},{"effect":"Coma","drugRate":"LLR 126","severity":"common"},{"effect":"Hypothermia","drugRate":"LLR 85","severity":"common"},{"effect":"Toxicity to various agents","drugRate":"LLR 71","severity":"common"},{"effect":"Suicide attempt","drugRate":"LLR 70","severity":"common"},{"effect":"Meningioma","drugRate":"LLR 64","severity":"common"},{"effect":"Hepatocellular injury","drugRate":"LLR 60","severity":"common"},{"effect":"Alkalosis hypochloraemic","drugRate":"LLR 59","severity":"common"},{"effect":"Bradycardia","drugRate":"LLR 57","severity":"common"},{"effect":"Hypometabolism","drugRate":"LLR 53","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"dipropylacetamide","offLabel":[],"synonyms":["valpromide","2-propylpentamide","dipropylacetamide"],"timeline":[],"approvals":[],"brandName":"Dipropylacetamide","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"valpromide","explanation":"Think of neurotransmitters like messengers that help different parts of the brain talk to each other. Valpromide helps regulate the amount of these messengers, which can help balance brain activity and treat certain conditions. By doing so, it can help reduce symptoms of anxiety, depression, and other mental health conditions.","oneSentence":"Valpromide works by modulating the activity of certain neurotransmitters in the brain.","technicalDetail":"Valpromide is a GABA receptor agonist and NMDA receptor antagonist, which means it binds to and activates GABA receptors, increasing the inhibitory effects of GABA, and blocks NMDA receptors, reducing excitatory neurotransmission."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2804","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=VALPROMIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VALPROMIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T16:12:38.249200","biosimilars":[],"competitors":[{"drugName":"valproic acid","drugSlug":"valproic-acid","fdaApproval":"1978-02-28","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"aminobutyric acid","drugSlug":"aminobutyric-acid","fdaApproval":"","relationship":"same-class"},{"drugName":"vigabatrin","drugSlug":"vigabatrin","fdaApproval":"2009-08-21","patentExpiry":"Oct 17, 2042","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tiagabine","drugSlug":"tiagabine","fdaApproval":"1997-09-30","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"valpromide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"valproic-acid","brandName":"valproic acid","genericName":"valproic acid","approvalYear":"1978","relationship":"same-class"},{"drugId":"aminobutyric-acid","brandName":"aminobutyric acid","genericName":"aminobutyric acid","approvalYear":"","relationship":"same-class"},{"drugId":"vigabatrin","brandName":"vigabatrin","genericName":"vigabatrin","approvalYear":"2009","relationship":"same-class"},{"drugId":"tiagabine","brandName":"tiagabine","genericName":"tiagabine","approvalYear":"1997","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02556320","phase":"NA","title":"Immunological and Viral Parameters in Patients Receiving Anti-epileptic Drugs","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2013-05","conditions":["Epilepsy","Drug Hypersensitivity Syndrome"],"enrollment":30,"completionDate":"2015-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005370","UNII":"RUA6CWU76G","INN_ID":"4365","RXNORM":"23420","UMLSCUI":"C0058426","ChEMBL_ID":"CHEMBL93836","KEGG_DRUG":"D02766","DRUGBANK_ID":"DB04165","PDB_CHEM_ID":" VPR","PUBCHEM_CID":"71113","SNOMEDCT_US":"698808002","SECONDARY_CAS_RN":"1116-24-1","MESH_SUPPLEMENTAL_RECORD_UI":"C004651"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"68%"},"publicationCount":159,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N03AG02","allCodes":["N03AG02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Aug 25","pmid":"40856063","title":"Valproic Acid Inhibits RhoA-Mediated Vascular Smooth Muscle Cell Contraction.","journal":"Journal of Korean medical science"},{"date":"2025 Aug 26","pmid":"40700674","title":"Trends in Prenatal Exposure to Antiseizure Medications Over the Past Decade: A Nationwide Study.","journal":"Neurology"},{"date":"2024 Nov 28","pmid":"39426425","title":"LC-MS/MS profiling of the poisonous wild mushroom, Entoloma mastoideum, (Entolomataceae, Basidiomycota) in Sabah (Northern Borneo), Malaysia.","journal":"Toxicon : official journal of the International Society on Toxinology"},{"date":"2024","pmid":"38635661","title":"Transcriptome analysis of Burkitt lymphoma cells treated with anti-convulsant drugs that are inhibitors of Epstein-Barr virus lytic reactivation.","journal":"PloS one"},{"date":"2023 Dec","pmid":"37838533","title":"Corrigendum to \"Valproate, divalproex, valpromide: Are the differences in indications justified?\" [Biomed. Pharmacother., 158 (2023) 114051].","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dipropylacetamide is an anti-epileptic drug that has been studied in clinical trials for the treatment of epilepsy. It has also been investigated in relation to drug hypersensitivity syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}